RIVERSTONE HOLDINGS LIMITED (SGX:AP4)
Riverstone - 2021 Strong Earnings Beat, Juicy Dividend Declared.
- Riverstone reported record high revenue and net profit as ASPs surged, in line with our estimates. Healthcare glove ASPs continue to normalise as demand softens while cleanroom glove ASPs remains steady from strong secular demand.
- Riverstone’s planned S$1.5b phase 7 expansion has been delayed by a year, reaching 12b in total capacity by end-22.
Riverstone's robust 2021 results in line with expectations.
- Riverstone (SGX:AP4) reported record-high revenue and net profit as 2021 ASPs surged due to overwhelming nitrile gloves demand. 2021 revenue (+68.5% y-o-y) and net profit (+119.1% y-o-y) skyrocketed, forming 96.3% and 100.0% of our 2021 forecasts. Gross profit rose by 112.4% y-o-y as ASPs rose sharply in 2021.
- Pending approval, Riverstone declared a special interim dividend of RM0.10, along with a final dividend of RM0.28, taking 2021 total dividend to RM0.48 (vs RM0.26 in 2020).
- Healthcare glove ASPs continuing downtrend in 2H21. Despite strong full-year results, Riverstone suffered double digit declines for both its 2H21 revenue (-11.7% y-o-y, -47.4% h-o-h) and net profit (-26.0% y-o-y, -63.8% h-o-h). The sharp declines were largely due to healthcare glove ASPs normalising nearer to pre-COVID-19 levels and lower utilisation rates in 4Q21 as the majority of Riverstone’s customers were clearing their unused inventory during that quarter.
- Management has noted that healthcare glove ASPs are currently US$30- 35/1000 pcs and they are expected to normalise further to US$25-30/1000 pcs in 1Q22, just slightly above pre-COVID-19 levels. However, management mentioned that 1Q22 has seen a recovery in both demand and utilisation rates as Riverstone’s customers restock their invetory for 2022 amid ongoing Omicron outbreaks.
- Cleanroom glove ASPs stable amid growing demand. ASPs for Riverstone’s higher margin cleanroom gloves remained stable at US$110-120/1000pcs as of 4Q21, supported by demand from long-term tech (semicons, electronics) customers. Management noted that the cleanroom glove segment remains a top priority for Riverstone and is expected to allocate more lines from upcoming expansions to tackle rising demand. We expect 2022 cleanroom ASPs to remain stable.
Phase 7 expansion delayed.
- Due to COVID-19 outbreaks in Malaysia, 1.5b pcs of new capacity from Riverstone’s phase 7 expansion has been delayed to end-22, leaving current total capacity at around 11b pcs. However, expansion plans have since resumed and Riverstone is expected to achieve 12b pcs by end-22, with an additional 1.5b pcs by end-23.
Riverstone - Earnings forecast revision and recommendation
- We cut our 2022 and 2023 earnings forecast for Riverstone by 14.9% and 11.3% of a new lethal COVID-19 variant.
- See
- Catalysts:
- Resurgence of COVID-19 infections.
- Better-than-expected demand for cleanroom gloves.
- Discovery of a new lethal COVID-19 variant.
Llelleythan Tan
UOB Kay Hian Research
|
John Cheong
UOB Kay Hian
|
https://research.uobkayhian.com/
2022-02-24
SGX Stock
Analyst Report
0.82
UP
0.680
